₹80.73
+0.93% today
· 30d +1.34%
as of 2026-09-04
Price · Daily Candles
“Anuh Pharma's Profit Dips, FIIs Enter as Share Price Falters from 52-Week High.”
Anuh Pharma faces headwinds as Q4 net profit declined by 6.23% YoY despite a 2.01% revenue increase, and its annual net profit dropped 13.32% for FY26. The stock trades at a TTM PE of 18.34, significantly below peers like Sun Pharma (40.41) and Divi's Lab (69.81), yet its share price has fallen 26.72% over the last year.
BULL CASE
+The stock is trading at a TTM P/E of 18.34 and P/B of 2.17, indicating a valuation considerably lower than some larger sector peers like Sun Pharma (PE 40.41) and Divis Lab (PE 69.81), and similar to Dr. Reddy's Lab (PE 19.55).
+Its 3-year revenue CAGR stands at 13.08%, with a 5-year CAGR of 11.76%, demonstrating consistent top-line expansion.
+Shareholding data shows a new FII stake of 0.05% in Q4 2026, which was not present in the prior quarter.
+The company's Machine Learning sales growth prediction for 1-year recent (2-year lookback) stands at a neutral 0.515 rank.
BEAR CASE
−Net profit in Q4 FY26 declined 6.23% YoY to ₹12.0 Cr, despite a marginal revenue increase of 2.01% YoY.
−Annual net profit witnessed a significant drop of 13.32% YoY in FY26 to ₹41.0 Cr.
−The stock has delivered a negative return of -26.72% over the last year and is trading 33.42% below its 52-week high of ₹114.9.
−Operating profit margin (OPM) decreased by 0.78% QoQ, falling to 9.27% in Q4 FY26.
−The ML prediction ranks for Free Cash Flow (FCF) over 1-year periods are weak across recent (0.027), rolling (0.171), and stable (0.101) lookbacks.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹194 Cr
+3.93% YoY
NET PROFIT
₹11 Cr
+37.63% YoY
OPM
9.84%
+2.63pp YoY
EPS
₹1.14
PE 18.34
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-1.3% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Anuh Pharma's TTM PE of 18.34 places it as a smaller player relative to industry giants, trading below the average PE of large-cap peers like Sun Pharma (40.41) and Cipla (29.52), for which the average ROCE is ~24%.
PEERPEROCE %
ANUHPHR18.34—
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
61
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
NEUTRAL
40
Valuation
CHEAP
75
Growth
MUTED
45
Profitability
DECENT
55
Technicals
STRONG
72
Risk
LOW
80
Key Stats
TTM PE
18.34
P/B
2.17
52W HIGH
₹94.89
OFF HIGH
-14.92%
DIV YIELD
1.97%
MKT CAP
₹809 Cr
◉ Active Signals
MACDBullish0.2801
RSI(14)Neutral55.0
⧉ Strategy Fit 🔒